Impact of G-CSF Prophweylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.

Date publication

mars 2022

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
Canton C, Boussari O, Boulin M, Le Malicot K, Taieb J, Dahan L, Lopez A, Lepage C, Bachet JB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35289915

Résumé

In metastatic pancreatic adenocarcinoma, few data are available on the use of granulocyte-colony stimulating factor (G-CSF) prophylaxis and its impact on dose-intensity (DI), or the link between DI and progression-free survival (PFS). This study assessed the impact of G-CSF prophylaxis on the DI received by patients and the relationship between full DI and PFS according to chemotherapy regimens.

Mots clés

dose-intensity, granulocyte-colony stimulating factor prophylaxis, metastatic pancreatic adenocarcinoma, progression-free survival, propensity score

Référence

Oncologist. 2022 Mar 15;: